ES2180622T3 - Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad. - Google Patents

Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad.

Info

Publication number
ES2180622T3
ES2180622T3 ES95904165T ES95904165T ES2180622T3 ES 2180622 T3 ES2180622 T3 ES 2180622T3 ES 95904165 T ES95904165 T ES 95904165T ES 95904165 T ES95904165 T ES 95904165T ES 2180622 T3 ES2180622 T3 ES 2180622T3
Authority
ES
Spain
Prior art keywords
tumorigenicity
oligonucleotidos
antisentido
inhibiting activity
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904165T
Other languages
English (en)
Inventor
Hofe Eric Von
Moshe Szyf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Aceragen Inc
Original Assignee
McGill University
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University, Hybridon Inc filed Critical McGill University
Application granted granted Critical
Publication of ES2180622T3 publication Critical patent/ES2180622T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A SECUENCIAS DE OLIGONUCLEOTIDOS ANTISENTIDO QUE INHIBEN LA GENERACION TUMORAL COMPLEMENTARIAS DEL ARNM O DEL ADN DE DOBLE CORDON QUE CODIFICA LA TRANSFERASA DE METILO DEL ADN DE LOS MAMIFEROS. LA INVENCION TAMBIEN SE REFIERE A LOS METODOS PARA INHIBIR LA GENERACION TUMORAL Y A LA COMPOSICION FARMACEUTICA QUE COMPRENDE EL NUCLEOTIDO ANTISENTIDO QUE INHIBE LA GENERACION TUMORAL.
ES95904165T 1993-12-01 1994-11-30 Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad. Expired - Lifetime ES2180622T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/161,673 US5578716A (en) 1993-12-01 1993-12-01 DNA methyltransferase antisense oligonucleotides

Publications (1)

Publication Number Publication Date
ES2180622T3 true ES2180622T3 (es) 2003-02-16

Family

ID=22582230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904165T Expired - Lifetime ES2180622T3 (es) 1993-12-01 1994-11-30 Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad.

Country Status (10)

Country Link
US (3) US5578716A (es)
EP (1) EP0731835B1 (es)
JP (1) JPH09511125A (es)
AT (1) ATE221914T1 (es)
CA (1) CA2177732C (es)
DE (1) DE69431164T2 (es)
DK (1) DK0731835T3 (es)
ES (1) ES2180622T3 (es)
PT (1) PT731835E (es)
WO (1) WO1995015378A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184211B1 (en) * 1993-11-30 2001-02-06 Methylgene Inc. Inhibition of DNA methyltransferase
US6645943B1 (en) * 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
AU3355297A (en) * 1996-05-22 1997-12-09 Mcgill University Specific inhibitors of dna methyltransferase enzyme
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
AU6592496A (en) * 1996-07-22 1998-02-10 Hybridon, Inc. Compositions and methods for treating specific gene expression-related diseases and disorders in humans
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6020318A (en) * 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
US7138384B1 (en) 1997-08-29 2006-11-21 The Regents Of The University Of California Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
ATE294388T1 (de) * 1997-08-29 2005-05-15 Univ California Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6066625A (en) * 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
ATE526406T1 (de) 1998-03-20 2011-10-15 Commw Scient Ind Res Org Kontrolle der genexpression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US7368551B2 (en) 1998-06-25 2008-05-06 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
US7342108B2 (en) * 1998-06-25 2008-03-11 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
EP1108018A1 (en) * 1998-08-31 2001-06-20 AstraZeneca AB Human deltex-like gene zdx
US6953783B1 (en) * 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
WO2000027795A1 (en) 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
EP1147204A1 (en) * 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US20030078216A1 (en) * 1999-05-03 2003-04-24 Macleod A. Robert Inhibition of histone deactylase
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1130120A3 (en) * 2000-01-26 2004-02-04 Nisshinbo Industries, Inc. Method for separating and collecting nucleic acids
AU2001240375A1 (en) * 2000-03-17 2001-10-03 Benitec Australia Limited Genetic silencing
EP1438404A2 (en) 2000-03-24 2004-07-21 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP2336166A1 (en) 2000-10-12 2011-06-22 University Of Rochester Compositions that inhibit proliferation of cancer cells
JP2004521614A (ja) * 2000-10-27 2004-07-22 インヴィトロジェン コーポレーション アンチセンスオリゴヌクレオチドを真核細胞に導入する方法
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
CA2369944A1 (en) * 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
BR0209056A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
CN1293073C (zh) * 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基烷氧基－、－烷硫基－和－烷基氨基吲哚衍生物
GB2392911A (en) * 2001-05-11 2004-03-17 Methylgene Inc Inhibitors of dna methyltransferase isoforms
US20040266718A1 (en) * 2001-08-06 2004-12-30 Zuomei Li Inhibition of specific histone deacetylase isoforms
EP1572168B1 (en) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
EP1575992A4 (en) 2002-08-05 2007-02-21 Univ Rochester CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
US7855323B2 (en) * 2004-02-10 2010-12-21 Monsanto Technology Llc Recombinant DNA for gene suppression
US20060075515A1 (en) 2004-08-11 2006-04-06 Luethy Michael H Enhanced zein reduction in transgenic corn seed
EP1574499A1 (en) * 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
MX2007008065A (es) * 2004-12-30 2008-03-04 Todd M Hauser Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
JP2008531647A (ja) * 2005-03-03 2008-08-14 ゲンチウム エスピーエー 抗腫瘍作用を有する製剤
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
ES2716874T3 (es) 2005-03-23 2019-06-17 Genmab As Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
WO2006107751A2 (en) * 2005-04-01 2006-10-12 Methylgene, Inc. Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon
MX2007014616A (es) 2005-05-20 2009-08-12 Methylgene Inc Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2010070380A2 (en) * 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US8816095B2 (en) * 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
CN103260627A (zh) 2010-11-12 2013-08-21 真蒂奥姆有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
JP2013198425A (ja) * 2012-03-24 2013-10-03 Kanagawa Univ オリゴヌクレオチドの製造方法
DK2864496T4 (da) 2012-06-22 2021-01-04 Gentium S R L Euglobulin-baseret fremgangsmåde til bestemmelse af den biologiske aktivitet af defibrotid
WO2014022116A2 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
AU2014219256B2 (en) 2013-02-21 2017-02-16 Sunshine Lake Pharma Co., Ltd. Heteroaromatic compounds as PI3 kinase modulators
WO2015077566A1 (en) 2013-11-21 2015-05-28 Huang Zhen Methods for structural determination of selenium derivatized nucleic acid complexes
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
WO2017067447A1 (en) 2015-10-19 2017-04-27 Sunshine Lake Pharma Co., Ltd. A salt of egfr inhibitor, crystalline form and uses thereof
JP2019527229A (ja) 2016-07-28 2019-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｐｒ１５６変異体及びその使用
US11123435B2 (en) 2016-08-03 2021-09-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
KR102619197B1 (ko) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
CA3065938A1 (en) 2017-06-05 2018-12-13 Regeneron Pharmaceuticals, Inc. B4galt1 variants and uses thereof
AU2018328120A1 (en) 2017-09-06 2020-03-19 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (SIGIRR) variants and uses thereof
RU2020112313A (ru) 2017-09-07 2021-10-08 Ридженерон Фармасьютикалз, Инк. Варианты члена 1 семейства 14 переносчиков растворенных веществ (slc14a1)и их применение
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
EP3695012B1 (en) 2017-10-11 2023-03-08 Regeneron Pharmaceuticals, Inc. Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
EP3697807A1 (en) 2017-10-16 2020-08-26 Regeneron Pharmaceuticals, Inc. Cornulin (crnn) variants and uses thereof
US11957687B2 (en) 2019-07-02 2024-04-16 Regeneron Pharmaceuticals, Inc. Modulators of HSD17B13 and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506944A4 (en) * 1990-10-23 1994-08-17 Hope City Mechanism based inhibitors of dna methyltransferase
EP0575518A1 (en) * 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression

Also Published As

Publication number Publication date
ATE221914T1 (de) 2002-08-15
CA2177732A1 (en) 1995-06-08
EP0731835A1 (en) 1996-09-18
PT731835E (pt) 2002-11-29
AU1296195A (en) 1995-06-19
DK0731835T3 (da) 2002-10-28
DE69431164D1 (de) 2002-09-12
US5578716A (en) 1996-11-26
DE69431164T2 (de) 2003-05-08
CA2177732C (en) 2004-04-27
JPH09511125A (ja) 1997-11-11
AU700264B2 (en) 1998-12-24
WO1995015378A1 (en) 1995-06-08
US5919772A (en) 1999-07-06
US6054439A (en) 2000-04-25
EP0731835B1 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
ES2180622T3 (es) Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad.
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
ATE171210T1 (de) Selbststabilisierte oligonukleotide als therapeutika
NO983716L (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
ATE309345T1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
DE69920247D1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
NO960965L (no) Genet Grb3-3 med varianter derav samt deres anvendelse
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
DE69932331D1 (de) Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit
DE60333747D1 (de) Dna-enzym zur hemmung von plasminogenaktivator-inhibitor-1
SE0302965D0 (sv) Hämmare av DNA-Metyltransferasisoformer
WO1998040478A3 (en) Antisense inhibition of human stat-6
BR0016347A (pt) Oligonucleotìdios antisenso